Last reviewed · How we verify
PHENIRAMINE MALEATE
At a glance
| Generic name | PHENIRAMINE MALEATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1994 |
Approved indications
Common side effects
Key clinical trials
- A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection (PHASE2)
- Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions. (PHASE2)
- Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects (NA)
- First-generation OTC Antihistamine Use and Voice Function: A Preliminary Study (EARLY_PHASE1)
- Chlorpheniramine Maleate Nasal Spray for Chronic Rhinitis (PHASE2, PHASE3)
- Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III (PHASE2, PHASE3)
- Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-I (PHASE2, PHASE3)
- Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Analysis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PHENIRAMINE MALEATE CI brief — competitive landscape report
- PHENIRAMINE MALEATE updates RSS · CI watch RSS